Clinical

Podcasts

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

Oncology Peer Review On-The-Go: Molecular Profiling Practices in Pancreatic Adenocarcinoma

Articles

The phase 1/2a trial reported favorable efficacy data in the first-line setting when compared with existing historical results for treating advanced pancreatic cancer.

Positive Results Seen in Trial Investigating Nadunolimab Plus Chemotherapy for Advanced Pancreatic Cancer

Videos

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.

Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward

Kim detailed the specifics of his research from the American Association for Cancer Research Annual Meeting 2021 focusing on novel therapies to target mutations and upstream or downstream pathways.

Michael Kim, MD, on Genetics and the Need for Novel Therapies in Pancreatic Cancer

The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.

Michael Kim, MD, Discusses Study on Mutant p53 and Oncogenic KRAS in Pancreatic Cancer

According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer 

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC 

Per a planned interim superiority analysis conducted by an independent data monitoring committee, a trial of Eryaspace will continue without modification with final results anticipated later this year.

Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final Analysis

Sohal spoke with CancerNetwork® regarding recent clinical data investigating 2 common pancreatic cancer treatment regimens: FOLFIRINOX and gemcitabine/nab-paclitaxel.

Davendra Sohal, MD, MPH, Discusses Major Takeaways From Key Research in Pancreatic Cancer

A study found a number of factors associated with increased recurrence risk for patients with locally advanced pancreatic neuroendocrine tumors following surgical resection, including sex, lymph node metastases, and resection of other organs with tumor involvement.

Pancreatic Cancer | Topics